Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells

Chimeric antigen receptor (CAR) T cell therapies have demonstrated impressive initial response rates in hematologic malignancies. However, relapse rates are significant, and robust efficacies in other indications, such as solid tumors, will likely require novel therapeutic strategies and CAR designs...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther
Main Authors: Qin, Haiying, Edwards, Justin P., Zaritskaya, Liubov, Gupta, Ankit, Mu, C. Jenny, Fry, Terry J., Hilbert, David M., LaFleur, David W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Gene & Cell Therapy 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612629/
https://ncbi.nlm.nih.gov/pubmed/31043341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2019.04.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados